
157 Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer
A. Gordon, A. TeitelbaumVolume:
1
Année:
2003
Langue:
english
DOI:
10.1016/s1359-6349(03)90190-x
Fichier:
PDF, 162 KB
english, 2003